Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Enhancing healthcare economics: the impact of manual dose rounding on T-DM1 costs in breast cancer treatment
Luotonen, H., Vuorinen, R. L., Tiainen, L., Kellokumpu-Lehtinen, P. L. & Bärlund, M., 2026, (E-pub ahead of print) In: Drugs and Therapy Perspectives. 6 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile1 Downloads (Pure) -
The evolution of cardiac changes after breast cancer adjuvant radiotherapy: A six-year follow-up study
Moisander, M., Tuohinen, S., Lähdeaho, H., Huhtala, H., Nikus, K., Virtanen, V., Kellokumpu-Lehtinen, P. L., Raatikainen, P. & Skyttä, T., Jan 2026, In: Clinical and translational radiation oncology. 56, 101078.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile3 Downloads (Pure) -
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial
SPCG-13 Investigators, Kellokumpu-Lehtinen, P. L., Fransson, A. S., Marttila, T., Lehtinen, I., Huttunen, T. & Thellenberg-Karlsson, C., Aug 2025, In: European Urology Oncology. 8, 4, p. 999-1002 4 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile3 Downloads (Pure) -
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
Azad, A., Arshad, M., Generali, D., Feldinger, K., Gijsen, M., Strina, C., Cappelletti, M., Andreis, D., Leek, R., Haider, S., Kellokumpu-Lehtinen, P. L., Roxanis, I., Harris, A. L., Shaaban, A. M., Joensuu, H. & Kong, A., 2025, In: Cancer Communications. 45, 1, p. 68-73Research output: Contribution to journal › Letter › Scientific
Open AccessFile2 Citations (Scopus)10 Downloads (Pure) -
Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012–2023
Kurko, T., Heino, P., Kellokumpu-Lehtinen, P.-L., Sarnola, K., Koskinen, H. & Bärlund, M., 2025, In: Cancers. 17, 19, 3162.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile2 Downloads (Pure)
Activities
-
High baseline Tie1 predicts poor survival in metastatic breast cancer
Tiainen, L. (Contributor), Korhonen, E. (Contributor), Luukkaala, T. (Contributor), Hämäläinen, M. (Contributor), Tanner, M. (Contributor), Lahdenperä, O. (Contributor), Vihinen, P. (Contributor), Jukkola, A. (Contributor), Karihtala, P. (Contributor), Moilanen, E. (Contributor), Alitalo, K. (Contributor) & Kellokumpu-Lehtinen, P. (Contributor)
21 Mar 2018Activity: Talk or presentation › Conference presentation
-
Kilpirauhassyövän sairastaneiden potilaiden kardiovaskulaarisairastavuus ja -kuolleisuus
Huhtala, H. (Contributor), Jaatinen, P. (Contributor) & Kellokumpu-Lehtinen, P.-L. (Contributor)
23 Mar 2017Activity: Talk or presentation › Conference presentation
-
Kilpirauhassyövän sairastaneiden potilaiden kardiovaskulaarisairastavuus ja -kuolleisuus
Pajamäki, N. (Contributor), Metso, S. (Contributor), Hakala, T. (Contributor), Ebeling, T. (Contributor), Huhtala, H. (Contributor), Ryödi, E. (Contributor), Sand, J. (Contributor), Kellokumpu-Lehtinen, P.-L. (Contributor), Jukkola-Vuorinen, A. (Contributor) & Jaatinen, P. (Contributor)
22 Mar 2017Activity: Talk or presentation › Conference presentation
-
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial
Joensuu, H. (Keynote speaker), Kellokumpu-Lehtinen, P.-L. (Keynote speaker), Huovinen, R. (Keynote speaker), Jukkola-Vuorinen, A. (Keynote speaker), Tanner, M. (Keynote speaker), Kokko, R. (Keynote speaker), Auvinen, P. (Keynote speaker), Lahdenperä, O. (Keynote speaker), Villman, K. (Keynote speaker), Nyandoto, P. (Keynote speaker), Nilsson, G. (Keynote speaker), Murashev, M. (Keynote speaker), Poikonen-Saksela, P. (Keynote speaker), Bono, P. (Keynote speaker), Kataja, V. (Keynote speaker) & Lindman, H. (Keynote speaker)
9 Jul 2016Activity: Talk or presentation › Invited lecture
-
A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer : Results of SPCG12
Tammela, T. (Speaker) & Kellokumpu-Lehtinen, P.-L. (Speaker)
7 Jun 2016Activity: Talk or presentation › Conference presentation